DK0773226T3 - Propiophenonderivater og fremgangsmåder til fremstilling deraf - Google Patents

Propiophenonderivater og fremgangsmåder til fremstilling deraf

Info

Publication number
DK0773226T3
DK0773226T3 DK96117088T DK96117088T DK0773226T3 DK 0773226 T3 DK0773226 T3 DK 0773226T3 DK 96117088 T DK96117088 T DK 96117088T DK 96117088 T DK96117088 T DK 96117088T DK 0773226 T3 DK0773226 T3 DK 0773226T3
Authority
DK
Denmark
Prior art keywords
processes
preparation
propiophenone derivatives
hydrogen atom
propiophenone
Prior art date
Application number
DK96117088T
Other languages
Danish (da)
English (en)
Inventor
Kenji Tsujihara
Kunio Saito
Mitsuya Hongu
Mamoru Matsumoto
Kozo Oka
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Application granted granted Critical
Publication of DK0773226T3 publication Critical patent/DK0773226T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK96117088T 1995-11-07 1996-10-24 Propiophenonderivater og fremgangsmåder til fremstilling deraf DK0773226T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7288487A JP3059088B2 (ja) 1995-11-07 1995-11-07 プロピオフェノン誘導体およびその製法

Publications (1)

Publication Number Publication Date
DK0773226T3 true DK0773226T3 (da) 1999-08-30

Family

ID=17730854

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96117088T DK0773226T3 (da) 1995-11-07 1996-10-24 Propiophenonderivater og fremgangsmåder til fremstilling deraf

Country Status (12)

Country Link
US (1) US5767094A (de)
EP (1) EP0773226B1 (de)
JP (1) JP3059088B2 (de)
KR (1) KR100333572B1 (de)
CN (1) CN1049222C (de)
AT (1) ATE175676T1 (de)
CA (1) CA2189603C (de)
DE (1) DE69601345T2 (de)
DK (1) DK0773226T3 (de)
ES (1) ES2128137T3 (de)
SG (1) SG40895A1 (de)
TW (1) TW460477B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU719726B2 (en) * 1996-12-26 2000-05-18 Tanabe Seiyaku Co., Ltd. Propiophenone derivatives and process for preparing the same
AU5755200A (en) 1999-08-27 2001-03-26 Joel R.L. Ehrenkranz Method of using dihydrochalcone derivatives to block glucose transfer
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
JP4590158B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
TW200524951A (en) * 2003-08-01 2005-08-01 Janssen Pharmaceutica Nv Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
EA010422B1 (ru) * 2003-08-01 2008-08-29 Янссен Фармацевтика Н.В. Замещённые индол-о-глюкозиды
RS20060320A (sr) * 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Supstituisani indazol-o-glukozidi
LT2896397T (lt) * 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
EP1679965A4 (de) * 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv Substituierte anellierte heterocyclische c-glycoside
FR2862303B1 (fr) * 2003-11-17 2006-01-06 Agronomique Inst Nat Rech Preparations colorantes hydrosolubles jaunes derivees des dihydrochalcones, leur procede des preparation, et leurs utilisations
TWI332707B (en) 2005-08-04 2010-11-01 Au Optronics Corp Array substrate of a liquid crystal display and method of fabricating the same
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
MX2010002695A (es) * 2007-09-10 2010-04-01 Janssen Pharmaceutica Nv Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt).
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US8791077B2 (en) 2008-05-22 2014-07-29 Astrazeneca Ab Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR101532412B1 (ko) 2009-07-10 2015-06-29 얀센 파마슈티카 엔.브이. 1-(β-Ｄ-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법
SI2488515T1 (sl) * 2009-10-14 2017-04-26 Janssen Pharmaceutica Nv Postopek za pripravo spojin, ki so uporabne kot inhibitorji SGLT2
TWI599360B (zh) 2010-05-11 2017-09-21 健生藥品公司 醫藥調配物
RS55056B1 (sr) 2011-04-13 2016-12-30 Janssen Pharmaceutica Nv Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
AU2021202643B2 (en) 2020-07-27 2023-02-02 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
EP4315350A1 (de) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systeme und verfahren zur verwaltung von prädiabetes mit einer pharmazeutischen gliflozin-natrium-glucose-cotransport-2-inhibitorzusammensetzung
US20250108065A1 (en) 2022-01-26 2025-04-03 Astrazeneca Ab Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
WO2025125513A1 (en) 2023-12-15 2025-06-19 AstraZeneca Ireland Limited Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760135A (en) * 1984-09-06 1988-07-26 University Of Kentucky Research Foundation Phloretin and phlorizin derivative containing compounds
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same

Also Published As

Publication number Publication date
JPH09124686A (ja) 1997-05-13
SG40895A1 (en) 1997-06-14
MX9605415A (es) 1997-10-31
DE69601345D1 (de) 1999-02-25
CN1049222C (zh) 2000-02-09
CA2189603A1 (en) 1997-05-08
CA2189603C (en) 2003-06-10
EP0773226A1 (de) 1997-05-14
KR100333572B1 (ko) 2002-09-18
CN1151405A (zh) 1997-06-11
KR970027098A (ko) 1997-06-24
US5767094A (en) 1998-06-16
DE69601345T2 (de) 1999-06-17
ATE175676T1 (de) 1999-01-15
EP0773226B1 (de) 1999-01-13
ES2128137T3 (es) 1999-05-01
JP3059088B2 (ja) 2000-07-04
TW460477B (en) 2001-10-21

Similar Documents

Publication Publication Date Title
DK0773226T3 (da) Propiophenonderivater og fremgangsmåder til fremstilling deraf
HU9600834D0 (en) Quinazoline derivatives
IL148384A0 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
AU6601294A (en) Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
EP0866059A4 (de) Neue heterozyklische derivate und ihre medizinische anwendung
ATE225770T1 (de) Difluoroprostaglandin-derivate und ihre anwendung
AU1282495A (en) Anthranilic acid derivative
DE69418243D1 (de) N-Heteroaryl-N'-Phenylharnstoffderivate, ihre Herstellung und Verwendung
AU697679B2 (en) Treatment of tinnitis using neuroprotective agents
ES2163425T3 (es) Uso de raloxifeno y de sus analogos para la fabricacion de un medicamento para el tratamiento de la ateroesclerosis y la enfermedad cardiaca isquemica.
AU3636089A (en) Hydrazine derivatives for pharmaceutical use
DK0508740T3 (da) Thiazolidindionderivater, deres fremstilling og anvendelse.
EP1031556A4 (de) 2-phenoxyanilin-derivate
EP0342587A3 (de) Thienotriazolodiazepine und ihre pharmazeutische Verwendung
EP1034783A4 (de) Amidederivaten
ES2196174T3 (es) `derivados de sesquiterpeno de actividad antiviral.
ES2168119T3 (es) Derivados de quinoxalina para el tratamiento de tinnitus.
AU2532692A (en) Method for treating hypertension
AU7962000A (en) Us0027324for eating disorders
DK0638587T3 (da) Salmyciner, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel